BSEBoard Meeting19 Oct 2026 · 19 Oct 2026, 03:47 pm

Marksans Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve Unaudited Financial Results of the Company (both Standalone and Consolidated) for the quarter and half year ended September 30, 2026

Marksans Pharma Ltd · 524404

✦ AI SummaryResults

Marksans Pharma Ltd has scheduled a Board Meeting on November 4, 2026, to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2026.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Marksans Pharma Ltd - 524404 - Board Meeting Intimation for Declaration Of Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026

Attachments (1)

📄

2c54be6a-279c-4d3f-95cf-d2eb57b7577e.pdf

pdf

Download →
View document text
October 19, 2026 BSE Limited National Stock Exchange of India Limited Corporate Relation Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block - G Dalal Street Bandra-Kurla Complex Mumbai – 400001 Bandra (East), Mumbai - 400051 Scrip Code: 524404 Symbol: MARKSANS Sub: Intimation of Board Meeting Dear Sir/Madam, Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) and other regulations, if applicable, we hereby inform the exchanges that a meeting of the Board of Directors of the Company will be held on Wednesday, November 04, 2026, inter alia, to consider and approve the Unaudited Financial Results of the Company (both Standalone and Consolidated) for the quarter and half year ended September 30, 2026. Kindly note that as per the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Company’s Internal Code on Prohibition of Insider Trading, the Trading Window for dealing in Company’s shares has been closed for the Company’s Designated Persons (including Directors) and their immediate relatives from October 01, 2026 and will remain closed till Forty-Eight hours after the announcement of the Financial Results i.e. up to November 06, 2026 (both days inclusive). Further, as per the Listing Regulations, this intimation of the Board Meeting would be available on the website of the Company i.e. www.marksanspharma.com, BSE Limited i.e. www.bseindia.com and National Stock Exchange of India Limited i.e. www.nseindia.com. We request you to take the aforesaid on records. Thanking you. Yours faithfully, For Marksans Pharma Limited Harshavardhan Panigrahi Company Secretary Marksans Pharma Ltd. 11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000 E-mail: companysecretary@marksanspharma.com www.marksanspharma.com